Ann: Mesoblast Update on Chronic Low Back Pain Program, page-137

For those that think the CLPB meeting at the FDA would be tepidly received, I suggest they take a look at the present head of the FDA (Woodcock) who Biden wants to stay, but has been roundly criticised in her role given her involvement in the Opioid epedemic that ravages the US. SI has given you the figures for back-pain related use.

The present head of the FDA needs a win on Opioids to secure her tenure and along comes MSB with some rather compelling results on reducing Opioid US in the US by addressing the main reason they are prescribed.

https://pharmaphorum.com/views-and-analysis/dilemma-for-biden-as-woodcocks-audition-for-fda-chief-stumbles/

You saw that cronyism under Biden has not gone, just changed direction with postive pushed; Aduhelm against the wishes of nearly every member on the panel, for an affliction that not only is Biden strong on, is probably afflicted by - Alzheimer's disease being the most common type of dementia.

The Opioid argument is not without some weight for the FDA, IMO.